DCDS 0780AAlternative Names: DCDS0780A
Latest Information Update: 27 Sep 2016
At a glance
- Originator Roche
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 16 Apr 2015 Roche plans a phase I trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) is USA (NCT02453087)
- 15 Apr 2015 Preclinical trials in Non-Hodgkin's lymphoma in Switzerland (IV)